<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33860698</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5-6</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Recruitment of population-based controls for ALS cases from the National ALS Registry.</ArticleTitle><Pagination><StartPage>395</StartPage><EndPage>400</EndPage><MedlinePgn>395-400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1887262</ELocationID><Abstract><AbstractText><i>Objective:</i> In 2010, the United States Agency for Toxic Substances and Disease Registry (ATSDR) created the National ALS Registry (Registry) to examine the epidemiology of ALS and potential risk factors. We are currently recruiting population-based controls for an epidemiologic case-control study to examine ALS environmental risk factors using this Registry. To date, we have recruited 181 non-diseased, population-based controls for comparison to Registry cases (<i>n</i>&#x2009;=&#x2009;280). Here we report our recruitment methods for controls and the associated response rates and costs. <i>Methods</i>: Eligible ALS cases had complete risk factor survey data, DNA analysis, and blood concentrations of persistent organic pollutants (POPs). Age, sex, and county-matched controls were identified from commercial/consumer databases using a targeted landline phone sample. Eligible controls were consented, surveyed, and mailed the POPs' blood analysis consent form. Once consented, phlebotomy was scheduled. <i>Results</i>: We mailed 3760 recruitment letters for 181 potential case-matches across 42 states between 9/2018 and 3/2020. After making phone contact and determining eligibility, 146 controls agreed to participate (response rate = 11.4%, cooperation rate = 22.8%). To date, 127 controls completed the survey and bloodwork. Though controls were matched to cases on age, sex, and county, unmatched characteristics (e.g. smoking) did not differ statistically. Interviewing and incentive costs are estimated at $211.85 per complete participation. <i>Conclusions</i>: Recruiting matched population-based controls for comparison to cases from the Registry for a study involving completion of a detailed survey and blood specimen provision is relatively feasible and cost effective. This recruitment method could be useful for case-control studies of other rare disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bear</LastName><ForeName>Todd M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Graduate School of Public Health, Department of Behavioral and Community Health Sciences, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malek</LastName><ForeName>Angela M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foulds</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Graduate School of Public Health, Department of Behavioral and Community Health Sciences, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rager</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deperrior</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vena</LastName><ForeName>John E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Theodore C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, National ALS Registry, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, National ALS Registry, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>D Kevin</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, National ALS Registry, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbott</LastName><ForeName>Evelyn O</ForeName><Initials>EO</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA, and.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01TS000272</GrantID><Acronym>ACL</Acronym><Agency>ACL HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 TS000272</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">biorepository</Keyword><Keyword MajorTopicYN="N">controls</Keyword><Keyword MajorTopicYN="N">registry</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword></KeywordList><CoiStatement>Declaration of interest. The authors report no conflict of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the Agency for Toxic Substances and Disease Registry, the Centers for Disease Control and Prevention, and/or the United States Department of Health and Human Services (HHS).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>16</Day><Hour>8</Hour><Minute>38</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33860698</ArticleId><ArticleId IdType="mid">NIHMS1726680</ArticleId><ArticleId IdType="pmc">PMC9014325</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1887262</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Horton DK, Mehta P, Antao VC. Quantifying a nonnotifiable disease in the United States: the National Amyotrophic Lateral Sclerosis Registry model. JAMA 2014;312:1097&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550214</ArticleId><ArticleId IdType="pubmed">25057819</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond J, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010&#x2013;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:413&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946020</ArticleId><ArticleId IdType="pubmed">31131638</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton DK, Graham S, Punjani R, Wilt G, Kaye W, Maginnis K, et al. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19:126&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815888</ArticleId><ArticleId IdType="pubmed">29262737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryan L, Kaye W, Antao V, Mehta P, Muravov O, Horton DK. Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data. PLoS One. 2016;11:e0153683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4849726</ArticleId><ArticleId IdType="pubmed">27124833</ArticleId></ArticleIdList></Reference><Reference><Citation>The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. 9th ed. Washington, DC: AAPOR; 2016.</Citation></Reference><Reference><Citation>Mitsumoto HCD, Pioro EP, editor. Amyotrophic lateral sclerosis. Philadelphia, PA: FA Davis Company; 1998.</Citation></Reference><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg SJ
J L. Wireless substitution: Early release of estimates from the National Health Interview Survey, July&#x2013;December 2018: National Center for Health Statistics; 2019.  [cited 2020 August 27]. Available from: https://www.cdc.gov/nchs/nhis.htm.</Citation></Reference><Reference><Citation>Mehta P, Horton DK, Kasarskis EJ, Tessaro E, Eisenberg MS, Laird S, et al. CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions. MMWR Morb Mortal Wkly Rep. 2017;66:1379&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5751576</ArticleId><ArticleId IdType="pubmed">29267263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>